Ερευνητική δραστηριότητα στην Ελλάδα

Θεόδωρος Βασιλακόπουλος

Πνευμονολόγος

Αναπληρωτής Καθηγητής

Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών

Ειδικός Γραμματέας ΕΠΕ

μεθοδολογία

- Pubmed search
- Limits: 20 Οκτωβρίου 2010- 20 Νοεμβρίου 2011
- Αναζήτηση με:
  - Greece AND subject (π.χ COPD)
  - Όνομα γνωστών ερευνητών
  - κέντρο

μεθοδολογία: μειονεκτήματα

- Παραλήψεις-λάθη αναπόφευκτα
- Εκ προοιμίου συγνώμη

- Καμία αναφορά σε συγκεκριμένες εργασίες
  - Θεωρώ εαυτόν μη ειδικό να κρίνει όλα τα πεδία της ειδικότητος
  - Η κρίση ενός ατόμου έχει περιορισμένη αξία
- Η ερευνητική παραγωγή είναι τόσο μεγάλη
  που είναι αδύνατον (σε εμένα)
  να την διαβάσω με τη δέουσα προσοχή,
  πολλώ μάλλον δε να την αξιολογήσω

Τομείς δραστηριότητος

- Σύνδρομο Απνοιών στον ύπνο
- Άσθμα
- Νοσήματα υπεζωκότα
- Μηχανικό αερισμό
- Διάμεσες Πνευμονοπάθειες
- Χρόνια αποφρακτική πνευμονοπάθεια

Σύνδρομο Απνοιών Ύπνο

Effect of mediterranean diet vs prudent diet combined with physical activity on OSAS: a randomised trial.
Papandreou C, Schiza SE, Bouloukaki I, Hatzis CM, Kafatos AG, Siafakas NM, Tzanakis NE. Eur Respir J. 2011 Oct 27. [Epub ahead of print]

Effect of Mediterranean diet on lipid peroxidation marker TBARS in obese patients with OSAHS under CPAP treatment: a randomised trial.
Papandreou C, Schiza SE, Tzatzarakis MN, Kavalakis M, Hatzis CM, Tsatsakis AM, Kafatos AG, Siafakas NM, Tzanakis NE. Sleep Breath. 2011 Sep 15.

Prediction of obstructive sleep apnea syndrome in a large Greek population.
Bouloukaki I, Kapsimalis F, Mermigkis C, Kryger M, Tzanakis N, Panagou P, Moniaki V, Vlachaki EM, Varouchakis G, Siafakas NM, Schiza SE.
Sleep Breath. 2011 Dec;15(4):657-64.

Gluteal adipose-tissue polyunsaturated fatty-acids profiles and depressive symptoms in obese adults with obstructive sleep apnea hypopnea syndrome: a cross-sectional study.
Papandreou C, Schiza SE, Tsibinos G, Mermigkis C, Hatzis CM, Kafatos AG, Siafakas NM, Fragkiadakis GA, Tzanakis NE.
Pharmacol Biochem Behav. 2011 Apr;98(2):316-9.

C-reactive protein evolution in obstructive sleep apnoea patients under CPAP therapy.
Schiza SE, Mermigkis C, Panagiotis P, Bouloukaki I, Kallergis E, Tzanakis N, Tzortzaki E, Vlachaki E, Siafakas NM. Eur J Clin Invest. 2010 Nov;40:968-75.

Evidence of dysregulated affect indicated by high alexithymia in obstructive sleep apnea.
Nikolaou A, Schiza SE, Chatzi L, Koudas V, Fokos S, Solidaki E, Bitsios P.
J Sleep Res. 2011 Mar;20(1 Pt 1):92-100.

Σύνδρομο Απνοιών Ύπνο

Mean Platelet Volume and Platelet Distribution Width in non-diabetic subjects with Obstructive Sleep Apnoea Syndrome: New indices of severity?
Nena E, Papanas N, Steiropoulos P, Zikidou P, Zarogoulidis P, Pita E, Constantinidis TC, Maltezos E, Mikhailidis DP, Bouros D.
Platelets. 2011 Nov 10. [Epub ahead of print]

Sleepiness as a marker of glucose derequlation in obstructive sleep apnea.
Nena E, Steiropoulos P, Papanas N, Tsara V, Fitili C, Froudarakis ME, Maltezos E, Bouros D.
Sleep Breath. 2011 Jan 5. [Epub ahead of print]

Obstructive sleep apnoea syndrome promotes reversal albuminuria during sleep.
Daskalopoulou EG, Liavvas C, Nakas CT, Vlachogiannis EG, Bouros D, Dombros NV.
Sleep Breath. 2011 Sep;15(3):589-97.

Prevalence and clinical characteristics of obesity hypoventilation syndrome among individuals reporting sleep-related breathing symptoms in northern Greece.
Trakada GP, Steiropoulos P, Nena E, Constandinidis TC, Bouros D.
Sleep Breath. 2010 Dec;14(4):381-6.

How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis?
Mermigkis C, Stagaki E, Tryfon S, Schiza S, Amfilochiou A, Polychronopoulos V, Panagou P, Galanis N, Kallianos A, Mermigkis D, Kopanakis A, Varouchakis G, Kapsimalis F, Bouros D.
Sleep Breath. 2010 Dec;14(4):387-90.

Σύνδρομο Απνοιών Ύπνο

Average volume-assured pressure support in a 16-year-old girl with congenital central hypoventilation syndrome.
Vagiakis E, Koutsourelakis I, Perraki E, Roussos C, Mastora Z, Zakynthinos S, Kotanidou A.
J Clin Sleep Med. 2010 Dec 15;6(6):609-12.

Nasal inflammation in sleep apnoea patients using CPAP and effect of heated humidification.
Koutsourelakis I, Vagiakis E, Perraki E, Karatza M, Magkou C, Kopaka M, Roussos C, Zakynthinos S.
Eur Respir J. 2011 Mar;37(3):587-94.

Adherence to CPAP therapy improves quality of life and reduces symptoms among obstructive sleep apnea syndrome patients.
Avlonitou E, Kapsimalis F, Varouchakis G, Vardavas CI, Behrakis P.
Sleep Breath. 2011 Jun 11. [Epub ahead of print]

Σύνδρομο Απνοιών Ύπνο

Oxidative stress and inflammatory markers in the exhaled breath condensate of children with OSA.
Malakasioti G, Alexopoulos E, Befani C, Tanou K, Varlami V, Ziogas D, Liakos P, Gourgoulianis K, Kaditis AG.
Sleep Breath. 2011 Aug 3. [Epub ahead of print]

Interactions of obstructive sleep-disordered breathing with recurrent wheezing or asthma and their effects on sleep quality.
Malakasioti G, Gourgoulianis K, Chrousos G, Kaditis A.
Pediatr Pulmonol. 2011 Nov;46(11):1047-54.

Effects of adenotonsillectomy on R-R interval and brain natriuretic peptide levels in children with sleep apnea: a preliminary report.
Kaditis AG, Chaidas K, Alexopoulos EI, Varlami V, Malakasioti G, Gourgoulianis K.
Sleep Med. 2011 Aug;12(7):646-51.

Noninvasive ventilation in chronic respiratory failure: effects on quality of life.
Tsolaki V, Pastaka C, Kostikas K, Karetsi E, Dimoulis A, Zikiri A, Koutsokera A, Gourgoulianis KI.
Respiration. 2011;81(5):402-10.

Quantitative spectral analysis of vigilance EEG in patients with obstructive sleep apnoea syndrome: EEG mapping in OSAS patients.
Xiromeritis AG, Hatziefthimiou AA, Hadjigeorgiou GM, Gourgoulianis KI, Anagnostopoulou DN, Angelopoulos NV.
Sleep Breath. 2011 Jan;15(1):121-8.

Sleep Breath
DOI 10.1007/s11325-011-0613-y

EDITORIAL (INVITED)

Prediction formulas for nasal continuous positive airway pressure in patients with obstructive sleep apnea syndrome

Sophia E. Schiza · Izolde Bouloukaki

Received: 10 October 2011 / Revised: 25 October 2011 / Accepted: 26 October 2011

Since its original description in 1981 [1], continuous positive airways pressure (CPAP) is a well established effective and evidence-based treatment for moderate to severe obstructive sleep apnea (OSA) [2]. However, the determination of optimal CPAP pressure in the laboratory is time-consuming and expensive, contributing to delays in the treatment of this condition. As sleep laboratory availability and expense is an issue of concern, several other formula takes into account BMI and AHI in predicting the optimal CPAP pressure setting in Taiwanese population [9]. The authors found that there is no significant difference between the three formulas in predicting the optimal CPAP pressure setting and that the new formula performs better than the previous formulas, though the improved accuracy was not statistically or clinically significant.

΄Ασθμα:βασική έρευνα

Mitochondrial genetic background plays a role in increasing risk to **asthma**.

Zifa E, Daniil Z, Skoumi E, Stavrou M, Papadimitriou K, Terzenidou M, Kostikas K, Bagiatis V, Gourgoulianis KI, Mamuris Z.

Mol Biol Rep. 2011 Sep 24. [Epub ahead of print]

IL-28A (IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease.

Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, Kotenko SV, Sideras P, Lehr HA, Tepe M, Klucher KM, Doyle SE, Neurath MF, Finotto S, Andreakos E.

EMBO Mol Med. 2011 Jun;3(6):348-61.

΄Ασθμα:κλινική έρευνα

Asthma Control Test Is Correlated to FEV(1) and Nitric Oxide in Greek Asthmatic Patients: Influence of Treatment.

Papakosta D, Latsios D, Manika K, Porpodis K, Kontakioti E, Gioulekas D.

J **Asthma**. 2011 Nov;48(9):901-6.

Interactions of obstructive sleep-disordered breathing with recurrent wheezing or **asthma** and their effects on sleep quality.

Malakasioti G, Gourgoulianis K, Chrousos G, Kaditis A.

Pediatr Pulmonol. 2011 Nov;46(11):1047-54.

The effect of physiotherapy-based breathing retraining on **asthma** control.

Grammatopoulou EP, Skordilis EK, Stavrou N, Myrianthefs P, Karteroliotis K, Baltopoulos G, Koutsouki D.

J **Asthma**. 2011 Aug;48(6):593-601.

Osteopontin expression and relation to disease severity in human **asthma**.

Samitas K, Zervas E, Vittorakis S, Semitekolou M, Alissafi T, Bossios A, Gogos H, Economidou E, Lötvall J, Xanthou G, Panoutsakopoulou V, Gaga M.

Eur Respir J. 2011 Feb;37(2):331-41.

΄Ασθμα:κλινική έρευνα

Comparison in **asthma** and allergy prevalence in the two major cities in Greece: the ISAAC phase II survey.

Papadopoulou A, Hatziagorou E, Matziou VN, Grigoropoulou DD, Panagiotakos DB, Tsanakas JN, Gratziou C, Priftis KN.

Allergol Immunopathol (Madr). 2011 Nov;39(6):347-55.

Exhaled NO and exhaled breath condensate pH in the evaluation of **asthma** control.

Kostikas K, Papaioannou AI, Tanou K, Giouleka P, Koutsokera A, Minas M, Papiris S, Gourgoulianis KI, Taylor DR, Loukides S.

Respir Med. 2011 Apr;105(4):526-32.

Validity and reliability evidence of the **Asthma** Control Test--ACT in Greece.

Grammatopoulou EP, Stavrou N, Myrianthefs P, Karteroliotis K, Baltopoulos G, Behrakis P, Koutsouki D.

J **Asthma**. 2011 Feb;48(1):57-64.

Body mass index is associated with leukotriene inflammation in asthmatics.

Giouleka P, Papatheodorou G, Lyberopoulos P, Karakatsani A, Alchanatis M, Roussos C, Papiris S, Loukides S.

Eur J Clin Invest. 2011 Jan;41(1):30-8.

΄Ασθμα:ανασκοπήσεις

Current update on eosinophilic lung diseases and anti-IL-5 treatment.

Samitas K, Rådinger M, Bossios A. Recent Pat Antiinfect Drug Discov. 2011 Sep 1;6(3):189-205.

Exhaled nitric oxide in **asthma** in adults: the end is the beginning?

Kostikas K, Minas M, Papaioannou AI, Papiris S, Dweik RA. Curr Med Chem. 2011;18(10):1423-31. Review.

Induced sputum in **asthma**: from bench to bedside.

Bakakos P, Schleich F, Alchanatis M, Louis R. Curr Med Chem. 2011;18(10):1415-22. Review.

Exhaled breath condensate in **asthma**: from bench to bedside. Loukides S, Kontogianni K, Hillas G, Horvath I.

Curr Med Chem. 2011;18(10):1432-43. Review.

Asthma in the Elderly: Can We Distinguish It from COPD?

Tzortzaki EG, Proklou A, Siafakas NM. J Allergy (Cairo). 2011;2011:843543.

EDITORIAL:

Non-Invasive Assessment of Asthmatic Inflammation: From Bench to Bedside

Asthma is now recognized as a heterogeneous disease, based on clinical parameters, the type of inflammation, the response to treatment, the rate of exacerbations and, finally, the underlying control and/or severity. Attempts to apply the above diverse characteristics to the clinical presentation of the disease have led to the identification of different phenotypes, with significant overlapping. The field of non invasive techniques has been rapidly developed since the time that the fraction of exhaled nitric oxide (FeNO) was recognized as an easily measured mediator in the exhaled air [1]. At approximately the same time, induced sputum was recognized as a valuable technique for the identification of the inflammatory cellular population as well as for the evaluation of different mediators in sputum supernatants [2]. Exhaled breath condensate (EBC), a totally non invasive technique, gave us the opportunity to sample the airways in an even more easily applicable approach, but the several methodological pitfalls of this method prevent it from being an accurate procedure for the evaluation of airways inflammation [3]. The attempt to connect the whole asthma entity and its numerous phenotypes using those minimally invasive techniques, i.e. FeNO, induced sputum and EBC, involves two major steps: First, these techniques must become more widely accepted and applied and, second, we need data from large multicenter studies that will identify the distinct inflammatory characteristics of specific phenotypes.

Stelios Loukides

2nd Respiratory Medicine Department
University of Athens Medical School
Smolika 2 16673 Athens
Greece
Tel: +306944380549
Fax: +302107770423
E-mail: ssat@hol.gr

Konstantinos Kostikas

2nd Respiratory Medicine Department
University of Athens Medical School
Athens
Greece
Tel: +306944780616
Fax: +302441022370
E-mail: ktk@otenet.gr

Petros Bakakos

1st Respiratory Medicine Department
University of Athens Medical School
Athens
Greece
Tel: +306974748113
Fax: +302107770423
E-mail: petros44@hotmail.com

Νοσήματα υπεζωκότα

Impact of multidrug resistance on experimental empyema by Pseudomonas aeruginosa.

Giamarellos-Bourboulis EJ, Tzepi I, Tsovolou I, Spyridaki A, Tsaganos T, Vaki I, Kotsaki A, Polychronopoulos V.

Respiration. 2011;82(1):46-53

New challenges in medical thoracoscopy.

Froudarakis ME. Respiration. 2011;82(2):197-200.

Diagnostic accuracy of biomarkers of oxidative stress in parapneumonic pleural effusions.

Tsilioni I, Kostikas K, Kalomenidis I, Oikonomidi S, Tsolaki V, Minas M, Gourgoulianis KI, Kiropoulos TS.

Eur J Clin Invest. 2011 Apr;41(4):349-56.

Effect of histamine on the electrophysiology of the human parietal pleura.

Kouritas VK, Tsantsaridou A, Tepetes K, Tsilimingas N, Gourgoulianis KI, Molyvdas PA, Hatzoglou C.

Mol Cell Endocrinol. 2011 Jan 30;332(1-2):271-6.

Νοσήματα υπεζωκότα

Intrapleural r-tPA in association with low-molecular heparin may cause massive hemothorax resulting in hypovolemia.

Anevlavis S, Archontogeorgis K, Tzouvelekis A, Kouliatsis G, Pozova S, Bougioukas I, Bouros D, Froudarakis ME.

Respiration. 2011;81(6):513-6.

Translational advances in **pleural** malignancies.

Stathopoulos GT.

Respirology. 2011 Jan;16(1):53-63.

Prognostic value of C-reactive protein in parapneumonic effusions.

Skouras V, Boultadakis E, Nikoulis D, Polychronopoulos V, Daniil Z, **Kalomenidis** I, Gourgoulianis KI.

Respirology. 2011 Oct 13. doi: 10.1111/j.1440-1843.2011.02078.x. [Epub ahead of print]

Short-term safety of thoracoscopic talc pleurodesis for recurrent primary spontaneous pneumothorax: a prospective European multicentre study.

Bridevaux PO, Tschopp JM, Cardillo G, Marquette CH, Noppen M, Astoul P, Driesen P, Bolliger CT, **Froudarakis** ME, Janssen JP.

Eur Respir J. 2011 Oct;38(4):770-3.

Νοσήματα υπεζωκότα

A sulindac analogue is effective against malignant pleural effusion in mice.

Moschos C, Psallidas I, Cottin T, Kollintza A, Papiris S, Roussos C, Stathopoulos GT, Giannis A, **Kalomenidis** I.

Lung Cancer. 2011 Aug;73(2):171-5.

Diagnostic accuracy of biomarkers of oxidative stress in parapneumonic pleural effusions.

Tsilioni I, Kostikas K, **Kalomenidis** I, Oikonomidi S, Tsolaki V, Minas M, Gourgoulianis KI, Kiropoulos TS.

Eur J Clin Invest. 2011 Apr;41(4):349-56.

Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.

Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, **Kalomenidis** I, Roussos C, Fingleton B, Yull FE, Peebles RS Jr, Blackwell TS.

Am J Respir Crit Care Med. 2010 Nov 15;182(10):1273-81.

Intrapleural administration of lipoplatin in an animal model.

Froudarakis ME, Greillier L, Monjanel-Mouterde S, Koutsopoulos A, Devictor-Pierre B, Guilhaumou R, Karpathiou G, Botaitis S, Astoul P.

Lung Cancer. 2011 Apr;72(1):78-83.

Official Journal of the Asian Pacific Society of Respirology
Respirology

EDITORIAL

Beyond talc pleurodesis: Do we really need new methods?

Key words: iodopovidone, malignant pleural effusion, pleurodesis, pneumothorax, silver nitrate.

Chemical pleurodesis, that is, the induction of pleural inflammation to cause fibrosis and obliteration of the pleural space, is mainly used to prevent re-accumulation of malignant pleural effusions (MPE) and the recurrence of spontaneous pneumothorax (SP). Talc is probably the most effective sclerosant, study was not adequately powered to permit definite conclusions, it suggested that iodopovidone, which is a standard medical product that does not require any analysis or sterilization, is a reasonable alternative to medical talc. Notably, the findings from this study were in keeping with those from another recent small randomized trial that showed similar efficacy of iodopovidone and medical talc in patients with MPE secondary to breast cancer.[14]

Ioannis Kalomenidis MD
Second Department of Pulmonary Medicine, University of Athens School of Medicine, Atticon Hospital, Athens, Greece

beta2 induces pleurodesis significantly faster than talc. *Am. J. Respir. Crit. Care Med.* 2001; **163**: 640–4.
22 Kalomenidis I, Guo Y, Lane KB *et al.* Transforming growth factor-beta3 induces pleurodesis in rabbits and collagen production of human mesothelial cells. *Chest* 2005; **127**: 1335–40.

Πνευμονολόγοι και μηχανικός αερισμός:weaning

New insights into weaning from mechanical ventilation: left ventricular diastolic dysfunction is a key player.

Papanikolaou J, Makris D, Saranteas T, Karakitsos D, Zintzaras E, Karabinis A, Kostopanagiotou G, Zakynthinos E.

Intensive Care Med. 2011 Oct 6. [Epub ahead of print]

Diagnostic accuracy of the rapid shallow breathing index to predict a successful spontaneous breathing trial outcome in mechanically ventilated patients with chronic obstructive pulmonary disease.

Boutou AK, Abatzidou F, Tryfon S, Nakou C, Pitsiou G, Argyropoulou P, Stanopoulos I. Heart Lung. 2011 Mar-Apr;40(2):105-10.

Study of multiparameter respiratory pattern complexity in surgical critically ill patients during weaning trials.

Papaioannou VE, Chouvarda IG, Maglaveras NK, Pneumatikos IA. BMC Physiol. 2011 Jan 21;11:2.

Nitroglycerin can facilitate weaning of difficult-to-wean chronic obstructive pulmonary disease patients: a prospective interventional non-randomized study.

Routsi C, Stanopoulos I, Zakynthinos E, Politis P, Papas V, Zervakis D, Zakynthinos S. Crit Care. 2010;14(6):R204.

Changes of heart and respiratory rate dynamics during weaning from mechanical ventilation: a study of physiologic complexity in surgical critically ill patients.

Papaioannou VE, Chouvarda I, Maglaveras N, Dragoumanis C, Pneumatikos I. J Crit Care. 2011 Jun;26(3):262-72.

Πνευμονολόγοι και μηχανικός αερισμός

Intermittent recruitment with high-frequency oscillation/tracheal gas insufflation in ards.

Mentzelopoulos SD, Malachias S, Zintzaras E, Kokkoris S, Zakynthinos E, Makris D, Magira E, Markaki V, Roussos C, Zakynthinos SG.

Eur Respir J. 2011 Sep 1. [Epub ahead of print]

Scanographic comparison of high frequency oscillation with versus without tracheal gas insufflation in acute respiratory distress syndrome.

Mentzelopoulos SD, Theodoridou M, Malachias S, Sourlas S, Exarchos DN, Chondros D, Roussos C, Zakynthinos SG.

Intensive Care Med. 2011 Jun;37(6):990-9.

Effect of albuterol on expiratory resistance in mechanically ventilated patients.

Kondili E, Alexopoulou C, Prinianakis G, Xirouchaki N, Vaporidi K, Georgopoulos D.

Respir Care. 2011 May;56(5):626-32. Epub 2011 Jan 27.

Aerosol delivery of antimicrobial agents during mechanical ventilation: current practice and perspectives.

Michalopoulos A, Metaxas EI, Falagas ME.

Curr Drug Deliv. 2011 Mar;8(2):208-12. Review.

Πνευμονολόγοι και μηχανικός αερισμός:βασική έρευνα

Impaired phospholipases A2 production by stimulated macrophages from patients with acute respiratory distress syndrome.

Hatzidaki E, Nakos G, Galiatsou E, Lekka ME.

Biochim Biophys Acta. 2010 Nov;1802(11):986-94.

Rohrer's constant, K2, as a factor of determining inspiratory resistance of common adult endotracheal tubes.

Flevari AG, Maniatis N, Kremiotis TE, Siempos I, Betrosian AP, Roussos C, Douzinas E, Armaganidis A.

Anaesth Intensive Care. 2011 May;39(3):410-7.

Metabolic acidosis may be as protective as hypercapnic acidosis in an ex-vivo model of severe ventilator-induced lung injury: a pilot study.

Kapetanakis T, Siempos II, Metaxas E, Kopterides P, Agrogiannis G, Patsouris E, Lazaris A, Stravodimos K, Roussos C, Armaganidis A.

BMC Anesthesiol. 2011 Apr 13;11:8.

Mechanical ventilation-induced diaphragm disuse in humans triggers autophagy.

Hussain SN, Mofarrahi M, Sigala I, Kim HC, Vassilakopoulos T, Maltais F, Bellenis I, Chaturvedi R, Gottfried SB, Metrakos P, Danialou G,

Matecki S, Jaber S, Petrof BJ, Goldberg P.

Am J Respir Crit Care Med. 2010 Dec 1;182(11):1377-86.

Διάμεσες πνευμονοπάθειες

Medical Research Council dyspnea scale does not relate to fibroblast foci profusion in IPF.
Triantafillidou C, Manali ED, Magkou C, Sotiropoulou C, Kolilekas LF, Kagouridis K, Rontogianni D, Papiris SA.
Diagn Pathol. 2011 Apr 5;6:28.

Yin Yang-1(YY-1) expression in idiopathic pulmonary fibrosis.
Margaritopoulos GA, Antoniou KM, Soufla G, Vassalou E, Spandidos DA, Siafakas NM.
J Recept Signal Transduct Res. 2011 Apr;31(2):188-91.

HRCT findings in the lungs of non-smokers with neurofibromatosis.
Oikonomou A, Vadikolias K, Birbilis T, Bouros D, Prassopoulos P.
Eur J Radiol. 2011 Dec;80(3):e520-3.

8.
Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension.
Boutou AK, Pitsiou GG, Trigonis I, Papakosta D, Kontou PK, Chavouzis N, Nakou C, Argyropoulou P, Wasserman K, Stanopoulos I.
Respirology. 2011 Apr;16(3):451-8.

Διάμεσες πνευμονοπάθειες

Investigation of angiogenetic axis Angiopoietin-1 and -2/Tie-2 in fibrotic **lung diseases**: a bronchoalveolar lavage study.
Margaritopoulos GA, Antoniou KM, Karagiannis K, Vassalou E, Lasithiotaki I, Lambiri I, Siafakas NM.
Int J Mol Med. 2010 Dec;26(6):919-23.

How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis?
Mermigkis C, Stagaki E, Tryfon S, Schiza S, Amfilochiou A, Polychronopoulos V, Panagou P, Galanis N, Kallianos A, Mermigkis D, Kopanakis A, Varouchakis G, Kapsimalis F, Bouros D.
Sleep Breath. 2010 Dec;14(4):387-90.

Stem cell therapy for idiopathic **pulmonary fibrosis**: a protocol proposal.
Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Oikonomou A, Zissimopoulos A, Kolios G, Kakagia D, Paspaliaris V, Kotsianidis I, Froudarakis M, Bouros D.

Prevalence of **pulmonary** hypertension in patients with idiopathic **pulmonary fibrosis**: correlation with physiological parameters.
Papakosta D, Pitsiou G, Daniil Z, Dimadi M, Stagaki E, Rapti A, Antoniou K, Tzouvelekis A, Kontakiotis T, Tryfon S, Polychronopoulos V, Bouros D.
Lung. 2011 Oct;189(5):391-9. Epub 2011 Jun 11.

Static and dynamic mechanics of the murine lung after intratracheal bleomycin.
Manali ED, Moschos C, Triantafillidou C, Kotanidou A, Psallidas I, Karabela SP, Roussos C, Papiris S, Armaganidis A, Stathopoulos GT, Maniatis NA.
BMC Pulm Med. 2011 May 31;11:33.

Διάμεσες πνευμονοπάθειες: ανασκοπήσεις

Smoking and pulmonary fibrosis: novel insights.
Samara KD, Margaritopoulos G, Wells AU, Siafakas NM, Antoniou KM.
Pulm Med. 2011;2011:461439.

Bronchiolitis and bronchial disorders in interstitial lung disease.
Pappas K.
Curr Opin Pulm Med. 2011 Sep;17(5):316-24.

Clinical review: idiopathic pulmonary fibrosis acute exacerbations--unravelling Ariadne's thread.
Papiris SA, Manali ED, Kolilekas L, Kagouridis K, Triantafillidou C, Tsangaris I, Roussos C.
Crit Care. 2010;14(6):246.

Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic findings, treatment response, and prognosis.
Drakopanagiotakis F, Paschalaki K, Abu-Hijleh M, Aswad B, Karagianidis N, Kastanakis E, Braman SS, Polychronopoulos V.
Chest. 2011 Apr;139(4):893-900.

Διάμεσες πνευμονοπάθειες: ανασκοπήσεις

The Challenge of Acute Exacerbation of Pulmonary Fibrosis.
Antoniou KM, Cottin V.
Respiration. 2011 Sep 16. [Epub ahead of print]

Smoking and pulmonary fibrosis: novel insights.
Samara KD, Margaritopoulos G, Wells AU, Siafakas NM, Antoniou KM.
Pulm Med. 2011;2011:461439. Epub 2011 Jun 15.

Stem cell therapy in pulmonary fibrosis.
Tzouvelekis A, Antoniadis A, Bouros D.
Curr Opin Pulm Med. 2011 Sep;17(5):368-73.

Pulmonary hypertension in idiopathic pulmonary fibrosis: a review.
Pitsiou G, Papakosta D, Bouros D.
Respiration. 2011;82(3):294-304. Epub 2011 Jun 15.

Διάμεσες πνευμονοπάθειες



EDITORIAL

Editorial

Demosthenes Bouros

Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece

Correspondence to Professor Demosthenes Bouros, MD, PhD, FCCP, Head, Department of Pneumonology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece
Tel: +30 25510 75096; fax: +30 25510 76106;
e-mail: bouros@med.duth.gr, debouros@gmail.com

Current Opinion in Pulmonary Medicine 2011, 17:346–347

This issue of *Current Opinion in Pulmonary Medicine* contains articles that readers will find informative and thought provoking. Collard and colleagues (pp. 348–354) present a comprehensive care for the patient with idiopathic pulmonary fibrosis based on the recently published evidence-based guidelines on the management of idiopathic pulmonary fibrosis (IPF) by the expert committee endorsed by the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS) and the Latin American Thoracic Society (ALAT) [1]. IPF is a chronic, progressive and fibrotic form of diffuse lung disease occurring therapy, hold promise and should be aggressively pursued' [1]. Mesenchymal stem cells represent one of the most challenging and promising areas of novel therapeutic strategies in chronic lung diseases involving tissue repair and regeneration. Over the past years, a number of reports have suggested that both embryonic and adult tissue-derived stem cells can participate in the regeneration and repair of diseased adult organs including the lungs [3]. Of special interest, reviewed by Tzouvelekis *et al.* (pp. 368–373), are adipose derived stem cells, as they present with interesting therapeutic advantages compared with bone-marrow stem cells [4].

Understanding of the role of endogenous lung progenitor cells [5] will provide further insight into mechanisms of lung development and repair after injury and may also provide novel therapeutic strategies. It is hoped that new research programmes will provide further understanding of mechanisms of repair of lung injury and further provide a sound scientific basis for therapeutic use of stem and cell therapies in lung diseases [6].

American Thoracic Society Documents

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

Ganesh Raghu, Harold R. Collard, Jim J. Egan, Fernando J. Martinez, Juergen Behr, Kevin K. Brown, Thomas V. Colby, Jean-François Cordier, Kevin R. Flaherty, Joseph A. Lasky, David A. Lynch, Jay H. Ryu, Jeffrey J. Swigris, Athol U. Wells, Julio Ancochea, Demosthenes Bouros, Carlos Carvalho, Ulrich Costabel, Masahito Ebina, David M. Hansell, Takeshi Johkoh, Dong Soon Kim, Talmadge E. King, Jr., Yasuhiro Kondoh, Jeffrey Myers, Nestor L. Müller, Andrew G. Nicholson, Luca Richeldi, Moisés Selman, Rosalind F. Dudden, Barbara S. Griss, Shandra L. Protzko, and Holger J. Schünemann, on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis

This Official Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS), the Japanese Respiratory Society (JRS), and the Latin American Thoracic Association (ALAT) Was Approved by the ATS Board of Directors, November 2010, the ERS Executive Committee, September 2010, the JRS Board of Directors, December 2010, and the ALAT Executive Committee, November 2010

This Statement has been formally endorsed by the Society of Thoracic Radiology and by the Pulmonary Pathology Society

Am J Respir Crit Care Med Vol 183. pp 788–824, 2011

Pirfenidone for idiopathic pulmonary fibrosis

Published Online
May 14, 2011
DOI:10.1016/S0140-6736(11)60546-1

See Articles page 1760

In *The Lancet* today, Paul Noble and colleagues report the results of the CAPACITY programme (Clinical Studies Assessing Pirfenidone in idiopathic pulmonary fibrosis: Research of Efficacy and Safety Outcomes).[1] Two concurrent phase 3 clinical trials (studies 004 and 006) investigated the role of pirfenidone in patients with mild-endpoint. However, in that study a consistent pirfenidone treatment effect was found up to week 48 (p=0·005) and in the repeated-measures analysis of all study time-points (p=0·007). In study 004, high-dose pirfenidone improved progression-free survival (hazard ratio 0·64, 95% CI 0·44–0·95, p=0·023). In study 006, a significant reduction of usual interstitial pneumonia, and is considered as an epithelial–fibroblastic disorder, characterised by abnormal wound healing with excessive fibrosis and little inflammation.[9] These emerging data on pathogenesis have focused attention on antifibrotic drugs.

Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) is an orally bioavailable synthetic compound. Although its mechanism of action has not been fully established,

Demosthenes Bouros
Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, 68100 Greece
bouros@med.duth.gr

I declare that I have no conflicts of interest.

1 Noble PW, Albera C, Bradford WZ, et al, for the CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *Lancet* 2011; published online May 14. DOI:10.1016/S0140-6736(11)60405-4.

ΧΑΠ: παθογένεια, δείκτες

Hemoglobin, erythropoietin and systemic inflammation in exacerbations of **chronic obstructive pulmonary disease**.
Markoulaki D, Kostikas K, Papatheodorou G, Koutsokera A, Alchanatis M, Bakakos P, Gourgoulianis KI, Roussos C, Koulouris NG, Loukides S.
Eur J Intern Med. 2011 Feb;22(1):103-7.

Exhaled breath condensate pH as a biomarker of COPD severity in ex-smokers.
Papaioannou AI, Loukides S, Minas M, Kontogianni K, Bakakos P, Gourgoulianis KI, Alchanatis M, Papiris S, Kostikas K.
Respir Res. 2011 May 22;12:67.

Association of ET-1 gene polymorphisms with COPD phenotypes in a Caucasian population.
Kaparianos A, Sampsonas F, Lykouras D, Efremidis G, Drakatos P, Karkoulias K, Gogos C, Spiropoulos K.
Monaldi Arch Chest Dis. 2011 Jun;75(2):126-31.

Statins and outcome after hospitalization for COPD exacerbation: a prospective study.
Bartziokas K, Papaioannou AI, Minas M, Kostikas K, Banya W, Daniil ZD, Haniotou A, Gourgoulianis KI.
Pulm Pharmacol Ther. 2011 Oct;24(5):625-31. Epub 2011 Jun 28.

ΧΑΠ: πολιτική υγείας

Smoking cessation can improve quality of life among COPD patients: validation of the clinical COPD questionnaire into Greek.
Papadopoulos G, Vardavas CI, Limperi M, Linardis A, Georgoudis G, Behrakis P.
BMC Pulm Med. 2011 Feb 25;11:13.

A combination of the IPAG questionnaire and PiKo-6® flow meter is a valuable screening tool for COPD in the primary care setting.
Sichletidis L, Spyratos D, Papaioannou M, Chloros D, Tsiotsios A, Tsagaraki V, Haidich AB.
Prim Care Respir J. 2011 Jun;20(2):184-9, 1 p following 189.

Long-Term Oxygen Therapy in COPD: Factors Affecting and Ways of Improving Patient Compliance.
Katsenos S, Constantopoulos SH.
Pulm Med. 2011;2011:325362. Epub 2011 Sep 15.

The cost of COPD exacerbations: a university hospital--based study in Greece.
Geitona M, Hatzikou M, Steiropoulos P, Alexopoulos EC, Bouros D.
Respir Med. 2011 Mar;105(3):402-9.

ΧΑΠ: άσκηση

Anemia of **chronic disease** in **chronic obstructive pulmonary disease**: a case-control study of cardiopulmonary exercise responses.
Boutou AK, Stanopoulos I, Pitsiou GG, Kontakiotis T, Kyriazis G, Sichletidis L, Argyropoulou P.
Respiration. 2011;82(3):237-45. Epub 2011 May 11.

Effect of **pulmonary** rehabilitation on peripheral muscle fiber remodeling in patients with **COPD** in GOLD stages II to IV.
Vogiatzis I, Terzis G, Stratakos G, Cherouveim E, Athanasopoulos D, Spetsioti S, Nasis I, Manta P, Roussos C, Zakynthinos S.
Chest. 2011 Sep;140(3):744-52. Epub 2011 Apr 14.

Endothelin-1 polymorphisms involved in impaired exercise tolerance in **COPD** patients. A pilot study.
Sampsonas E, Lykouras D, Drakatos P, Moschopoulou A, Spiropoulos K, Karkoulias K.
Eur Rev Med Pharmacol Sci. 2011 Feb;15(2):123-8.

Effect of helium breathing on intercostal and quadriceps muscle blood flow during exercise in **COPD** patients.
Vogiatzis I, Habazettl H, Aliverti A, Athanasopoulos D, Louvaris Z, LoMauro A, Wagner H, Roussos C, Wagner PD, Zakynthinos S.
Am J Physiol Regul Integr Comp Physiol. 2011 Jun;300(6):R1549-59. Epub 2011 Mar 16.

ΧΑΠ: ανασκοπήσεις

Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations.
Tsiligianni I, Kocks J, **Tzanakis N**, Siafakas N, van der Molen T.
Prim Care Respir J. 2011 Sep;20(3):257-68.

Mechanisms of altered cell immunity and cytotoxicity in COPD.
Tsoumakidou M, Tsiligianni I, Tzanakis N.
Curr Drug Targets. 2011 Apr;12(4):450-9. Review.

Oxidative stress in patients with COPD.
Loukides S, Bakakos P, Kostikas K.
Curr Drug Targets. 2011 Apr;12(4):469-77. Review.

Respiratory muscle dysfunction in COPD: from muscles to cell.
Klimathianaki M, Vaporidi K, Georgopoulos D.
Curr Drug Targets. 2011 Apr;12(4):478-88. Review.

R204

The role of leptin in the respiratory system: an overview.
Malli F, Papaioannou AI, Gourgoulianis KI, Daniil Z.
Respir Res. 2010 Oct 31;11:152. Review.

Physiological techniques for detecting expiratory flow limitation during tidal breathing.
Koulouris NG, Hardavella G.
Eur Respir Rev. 2011 Sep 1;20(121):147-55.

ΧΑΠ: μοντέλα ζώων

MAPKs and NF-κB differentially regulate cytokine expression in the diaphragm in response to resistive breathing: the role of oxidative stress.
Sigala I, Zacharatos P, Toumpanakis D, Michailidou T, Noussia O, Theocharis S, Roussos C, Papapetropoulos A, **Vassilakopoulos** T.
Am J Physiol Regul Integr Comp Physiol. 2011 May;300(5):R1152-62.

Inspiratory resistive breathing induces acute lung injury.
Toumpanakis D, Kastis GA, Zacharatos P, **Sigala** I, Michailidou T, Kouvela M, Glynos C, Divangahi M, Roussos C, Theocharis SE,**Vassilakopoulos** T.
Am J Respir Crit Care Med. 2010 Nov 1;182(9):1129-36.

EDITORIALS

Preventing Exacerbations of COPD — Advice from Hippocrates

Nikolaos M. Siafakas, M.D., Ph.D.

Severe acute exacerbations of chronic obstructive pulmonary disease (COPD) are devastating, life-threatening events; the 30-day mortality is greater than that with acute myocardial infarction (26% vs. 7.8%).[1,2] Acute exacerbations of COPD dramatically change the course of the disease, since they are associated with a rapid decline in lung function and worsening quality of life.[3] They also represent a substantial economic burden to society.[3] Prevention of exacerbations remains a primary goal of management[3] but is difficult because the cause of acute exacerbations of COPD remains largely unknown.[4]

Recent studies have shown that, when used proximately 5% in the patients receiving azithromycin. More important, there was an increased prevalence of macrolide-resistant bacteria colonizing the airway, although this was not associated with an increased incidence of pneumonia, a finding that is in agreement with previous reports involving fewer patients.[7,8]

However, the risk of microbial resistance associated with the long-term use of azithromycin in patients with COPD must be considered as part of the risk–benefit ratio of this treatment. Although the effect on microbial resistance in the community is still unknown, the study by Albert et al. showed that among patients who

Μεθοδολογία:
σύγκριση με το παρελθόν: 10 έτη πριν

- Pubmed search
- Limits: 20 Οκτωβρίου 2010- 20 Νοεμβρίου 2011
- Limits: 20 Οκτωβρίου 2000- 20 Νοεμβρίου 2001
- Αναζήτηση με:
  - Greece AND subject (π.χ COPD)
  - Όνομα γνωστών ερευνητών
  - Κέντρο

Στατιστικά δεδομένα

Impact factor 2010

- Συνολικός αριθμός αναφορών το 2010 σε άρθρα που δημοσιεύτηκαν στο περιοδικό κατά τα έτη 2008 και 2009

- Συνολικό αριθμό των άρθρων που δημοσιεύτηκαν στο περιοδικό κατά τα έτη 2008 και 2009

Impact factor 10

το 2010
τα άρθρα που δημοσιεύτηκαν στο περιοδικό
κατά τα έτη 2008 και 2009
ελάμβαναν 10 αναφορές
κατά μέσο όρο

Journal Citation Reports®

WELCOME | HELP | MARKED LIST

2010 JCR Science Edition

Journal Summary List

Journal Title Changes

Journals from: subject categories RESPIRATORY SYSTEM VIEW CATEGORY SUMMARY LIST

Sorted by: Impact Factor SORT AGAIN

Journals 1 - 20 (of 46) [1 | 2 | 3] **Page 1 of 3**

MARK ALL | UPDATE MARKED LIST

Ranking is based on your journal and sort selections.

Mark	Rank	Abbreviated Journal Title (linked to journal information)	ISSN	JCR Data						*Eigenfactor*™ Metrics	
				Total Cites	Impact Factor	5-Year Impact Factor	Immediacy Index	Articles	Cited Half-life	*Eigenfactor*™ Score	*Article Influence*™ Score
☑	1	AM J RESP CRIT CARE	1073-449X	44997	10.191	10.019	2.081	310	8.2	0.10676	3.483
☑	2	THORAX	0040-6376	15645	6.525	6.686	1.290	162	8.0	0.03418	2.178
☑	3	CHEST	0012-3692	42764	6.519	5.627	1.346	384	7.8	0.09420	1.752
☑	4	EUR RESPIR J	0903-1936	22321	5.922	6.218	1.328	302	6.8	0.05695	1.906
☑	5	AM J RESP CELL MOL	1044-1549	9934	4.426	4.482	1.200	165	7.5	0.02601	1.635
☑	6	AM J PHYSIOL-LUNG C	1040-0605	12579	4.137	4.244	0.521	188	6.5	0.03623	1.409
☑	7	J THORAC ONCOL	1556-0864	3350	4.040	4.086	0.413	346	2.7	0.01959	1.290

☑	8	ANN THORAC SURG	0003-4975	27678	3.792	3.100	0.808	510	7.8	0.06271	0.997
☑	9	J THORAC CARDIOV SUR	0022-5223	19274	3.608	3.610	0.606	492	8.0	0.04709	1.284
☑	10	J HEART LUNG TRANSPL	1053-2498	6798	3.426	3.096	0.805	185	5.4	0.02251	0.947
☑	11	LUNG CANCER	0169-5002	6396	3.356	3.258	0.864	242	5.0	0.02063	0.938
☑	12	CLIN CHEST MED	0272-5231	1812	3.110	2.665	0.119	59	7.6	0.00501	0.940
☑	13	CURR OPIN PULM MED	1070-5287	1694	2.906	2.704	0.678	90	4.8	0.00616	0.840
☑	14	RESP RES	1465-9921	2812	2.859	3.730	0.350	183	4.6	0.01368	1.181
☑	15	J CYST FIBROS	1569-1993	1088	2.840		0.414	70	3.3	0.00513	
☑	16	PAEDIATR RESPIR REV	1526-0542	865	2.676		0.639	36	5.0	0.00297	
☑	17	TUBERCULOSIS	1472-9792	1461	2.650	2.749	0.420	50	4.5	0.00597	0.930
☑	18	INT J TUBERC LUNG D	1027-3719	5266	2.557	2.426	0.402	271	5.6	0.01851	0.851
☑	19	RESPIRATION	0025-7931	2667	2.543	2.272	0.726	124	6.3	0.00588	0.576
☑	20	RESP MED	0954-6111	5656	2.525	2.453	0.391	261	4.9	0.01735	0.676

μεθοδολογία

- Impact factor
  - Πρωτότυπες εργασίες (original papers)
  - Ανασκοπήσεις
  - Όχι σε letters, case reports, editorials, comments
- Περιοδικά χωρίς impact factor: 0
  - Στο μέλλον μπορεί να αποκτήσουν
- Εργασίες αποδόθηκαν **(στο μέτρο του δυνατού)**
  στις κλινικές που παρήχθησαν
  και όχι στην κλινική που δουλεύει σήμερα η/ο συνάδελφος

Για παράδειγμα…

☐

Effect of pulmonary rehabilitation on peripheral muscle fiber remodeling in patients with COPD in GOLD stages II to IV.

Vogiatzis I, Terzis G, **Stratakos G**, Cherouveim E, Athanasopoulos D, Spetsioti S, Nasis I, Manta P, Roussos C, Zakynthinos S.

Chest. 2011 Sep;140(3):744-52.

☐

Clinical prediction of pulmonary embolism in respiratory emergencies.

Tsimogianni AM, **Rovina N**, Porfyridis I, Nikoloutsou I, Roussos C, Zakynthinos SG, **Stathopoulos GT**.

Thromb Res. 2011 May;127(5):411-7.

μεθοδολογία

- Μία τυχαία συγκεκριμένη περίοδος δεν εκφράζει την παραγωγικότητα ενός τμήματος ή ερευνητού
- Οι αριθμοί δεν αποκαλύπτουν από μόνοι τους την πραγματικότητα
- Παραλήψεις-λάθη αναπόφευκτα
- Εκ προοιμίου συγνώμη

Πάρα ταύτα….

Η πραγματικότητα είναι τόσο ευχάριστη

που δεν αφήνει καμία αμφιβολία

Τρόπος παρουσίασης

Οκτωβριος 2010 – Νοεμβριος 2011

Original Articles (συνεργασίες)	Mean Impact Factor	Reviews	Mean Impact Factor	Case reports
10 (4)	5,2	4 (2)	3	1

Σειρά παρουσίασης: αλφαβητική

ΑΡΙΣΤΟΤΕΛΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΟΝΙΚΗΣ
ΠΝΕΥΜΟΝΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ

Οκτωβριος 2010 – Νοεμβριος 2011

Original Articles	Mean impact factor	Reviews	Mean impact factor	Case reports
12(6)	1,67	2(2)	1,25	7

Οκτωβριος 2000 – Νοεμβριος 2001

Original Articles	Mean impact factor	Reviews	Mean impact factor	Case reports
3(1)	4,12	0		0

ΑΡΙΣΤΟΤΕΛΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΟΝΙΚΗΣ
«ΜΟΝΑΔΑ ΑΝΑΠΝΕΥΣΤΙΚΗΣ ΑΝΕΠΑΡΚΕΙΑΣ»

Οκτωβριος 2010 – Νοεμβριος 2011

Original Articles	Mean impact factor	Reviews	Mean impact factor	Case reports
5(2)	2,13	0		2

ΠΝΕΥΜΟΝΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ
ΔΗΜΟΚΡΙΤΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΡΑΚΗΣ

Οκτωβριος 2010 – Νοεμβριος 2011

Original Articles	Mean Impact Factor	Reviews	Mean Impact Factor	Case reports-comments
16 (8)	2.71	1 (1)	2.54	2 Editorials 1 Lancet (IF=33,6)

Οκτωβριος 2000 – Νοεμβριος 2001

Original Articles	Mean Impact Factor	Reviews	Mean Impact Factor	Case reports
0	0	0	0	0

ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΠΝΕΥΜΟΝΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΕΚΠΑ
ΝΟΣΟΚΟΜΕΙΟ «ΣΩΤΗΡΙΑ»

Οκτωβριος 2010 – Νοεμβριος 2011

Original Articles	Mean impact factor	Reviews	Mean impact factor	Case reports
9 (8)	1,68	4 (2)	1,92	2

Οκτωβριος 2000 – Νοεμβριος 2001

Original Articles	Mean impact factor	Reviews	Mean impact factor	Case reports
3 (1)	3,39	0		

ΠΝΕΥΜΟΝΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ
ΑΤΤΙΚΟ ΝΟΣΟΚΟΜΕΙΟ

Οκτωβριος 2010 – Νοεμβριος 2011

Original Articles	Mean impact factor	Reviews	Mean impact factor	Case reports
12 (10)	2,89	7 (5)	4,37	2+ 2 Editorials

ΠΝΕΥΜΟΝΟΛΟΓΙΚΟ ΤΜΗΜΑ Α' ΚΛΙΝΙΚΗ ΕΝΤΑΤΙΚΗΣ ΘΕΡΑΠΕΙΑΣ
ΝΟΣΟΚΟΜΕΙΟ «Ο ΕΥΑΓΓΕΛΙΣΜΟΣ»

Οκτωβριος 2010 – Νοεμβριος 2011

Original Articles (συνεργασίες)	Mean Impact Factor	Reviews	Mean Impact Factor	Case reports
12 (4)	5.99	0		1

Οκτωβριος 2000 – Νοεμβριος 2001

Original Articles	Mean Impact Factor	Reviews	Mean Impact Factor	Case reports
3 (2)	5.09	0		2

ΠΝΕΥΜΟΝΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ
ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΘΕΣΣΑΛΙΑΣ

Οκτωβριος 2010 – Νοεμβριος 2011

Original Articles	Mean impact factor	Reviews	Mean impact factor	Case reports
19 (7)	2,00	2 (0)	2,55	0

Οκτωβριος 2000 – Νοεμβριος 2001

Original Articles	Mean impact factor	Reviews	Mean impact factor	Case reports
7 (0)	1,25	0		1

ΠΝΕΥΜΟΝΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ
ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΙΩΑΝΝΙΝΩΝ

Οκτωβριος 2010 – Νοεμβριος 2011

Original Articles	Mean impact factor	Reviews	Mean impact factor	Case reports-letters
2	5,22	1	0	2

Οκτωβριος 2000 – Νοεμβριος 2001

Original Articles	Mean impact factor	Reviews	Mean impact factor	Case reports
1 (1)	2.53	0		0

ΠΝΕΥΜΟΝΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ
ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΚΡΗΤΗΣ

Οκτωβριος 2010 – Νοεμβριος 2011

Original Articles	Mean impact factor	Reviews	Mean impact factor	Case reports - comments
17 (4)	1,67	4 (2)	0,63	3 + 2 Editorials 1 NEJM (IF=53,5)

Οκτωβριος 2000 – Νοεμβριος 2001

Original Articles	Mean impact factor	Reviews	Mean impact factor	Other (case reports - comments)
10 (4)	2,09	0		1

ΠΝΕΥΜΟΝΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΠΑΤΡΩΝ

Οκτωβριος 2010 – Νοεμβριος 2011

Original Articles	Mean impact factor	Reviews	Mean impact factor	Other (case reports - comments)
3(1)	1,23	1		1

Οκτωβριος 2000 – Νοεμβριος 2001

Original Articles	Mean impact factor	Reviews	Mean impact factor	Other (case reports - comments)
2	1,27	0		0

Συμπέρασμα

- Βελτίωση της ερευνητικής παραγωγής παρά
  - Την υποχρηματοδότηση
  - Την υποστελέχωση
  - Την έλλειψη αποκλειστικού χρόνου για έρευνα

Ερευνητικές υποτροφίες ΕΠΕ

- «όαση» στην υποχρηματοδότηση
- Ευχαριστίες στις χορηγούς εταιρείες
- Παράκληση για περαιτέρω ενίσχυση
  - Πολυάριθμες αξιόλογες ερευνητικές προτάσεις

μέλλον=βελτίωση

- Μεγαλύτερη προσπάθεια
- Περαιτέρω βελτίωση της ποιότητας
  - Επιπλέον πείραμα-μέτρηση
  - Έστω και αν αυτό συνεπάγεται καθυστέρηση
- Να δημοσιεύουμε όταν έχουμε κάτι νέο να πούμε
- Peter Macklem: Do not litter the literature

Το πλεονέκτημα και ταυτόχρονα «μειονέκτημα» της έρευνας;

Το βιογραφικό συνδέεται άμεσα με την επαγγελματική προαγωγή

Μην ξεχνάμε τα απαραίτητα χαρακτηριστικά της έρευνας

- Ήθος
- Ειλικρίνεια
- Εστίαση
- Σεβασμό στους κανόνες
- Πραγματικές συνεργασίες
  - Όχι συνδιαλλαγές

American Journal of Respiratory & Critical Care Medicine
Instructions for authors

- **CRITERIA FOR AUTHORSHIP**
  Each author should have participated sufficiently in the work, the data analysis, and the preparation of the manuscript, and have reviewed and approve the manuscript as submitted to take public responsibility for it. This would include substantial participation in some or all of the following aspects of the work relating to the manuscript:
- involvement in the conception, hypotheses delineation, and design of the study
- acquisition of the data or the analysis and interpretation of such information
- writing the article or substantial involvement in its revision prior to submission

Έρευνα στην πνευμονολογία στην Ελλάδα 2011

- Είμαστε στο διεθνή χάρτη
  - Σε κάποιους τομείς σε περίοπτη θέση
- Ευχαριστίες
  - Στους δασκάλους μας για:
    - Αυτά που μας έμαθαν
    - Αυτά που δημιούργησαν
  - Στους μαθητές (όλων των ηλικιών)
    - Την προσπάθεια που κατέβαλαν
    - Τις ικανότητες

Ο εχθρός του καλού
είναι το καλύτερο